On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.

Journal for Immunotherapy of Cancer
Pablo NenclaresKevin Harrington

Abstract

Previous studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors (ICIs). We aimed to develop a model that predicts response and survival in patients with relapsed and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy. Analysis of 100 consecutive patients with unresectable R/M HNSCC who were treated with ICI. Baseline and on-treatment (day 28) NLR, fibrinogen and LDH were calculated and correlated with response, progression-free survival (PFS) and overall survival (OS) using univariate and multivariate analyses. The optimal cut-off values were derived using maximally selected log-rank statistics. Low baseline NLR and fibrinogen levels were associated with response. There was a statistically significant correlation between on-treatment NLR and fibrinogen and best overall response. On-treatment high NLR and raised fibrinogen were significantly associated with poorer outcome. In multivariate analysis, on-treatment NLR (≥4) and on-treatment fibrinogen (≥4 ng/mL) showed a significant negati...Continue Reading

References

Sep 28, 2005·Japanese Journal of Clinical Oncology·Hiroharu YamashitaHirokazu Nagawa
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik-Tobias ArkenauStan Kaye
Feb 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David OlmosStan B Kaye
Mar 29, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer WhelerRazelle Kurzrock
Apr 23, 2014·Journal of Korean Medical Science·Kyung Hee KimSeok-Chul Yang
May 31, 2014·Journal of the National Cancer Institute·Arnoud J TempletonEitan Amir
Oct 9, 2014·Blood Reviews·John C Chapin, Katherine A Hajjar
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P F FerrucciC Martinoli
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Aug 22, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Frédéric BigotChristophe Massard
Sep 2, 2018·Journal of Translational Medicine·Steven F JosephsAmir Jafri
Dec 14, 2018·Blood·James P LuyendykMatthew J Flick
Nov 2, 2019·International Journal of Molecular Sciences·Valerie CristinaMarco Siano
Nov 19, 2019·Frontiers in Cellular and Infection Microbiology·Mridula VardhanDeepak Saxena
Jul 2, 2020·Trends in Cancer·Qianqian DuanLianjun Zhang
Sep 22, 2020·Annals of Translational Medicine·Petr Szturz, Jan B Vermorken

❮ Previous
Next ❯

Software Mentioned

maxstat
GraphPad Prism
R
R studio

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.